Cd6 antibody for treatment of t-cell mediated diseases or disorders

Abstract

A method of treating a T-cell mediated disease in a subject by administering to the subject a therapeutically effective amount of an antibody or fragment thereof that specifically binds to CD6 is described. Humanized antibodies useful for the method are also described.

What is claimed is: 
     
         1 . A method of treating a T-cell mediated disease or disorder in a subject by administering to the subject a therapeutically effective amount of an antibody or fragment thereof that specifically binds to CD6. 
     
     
         2 . The method of  claim 1 , wherein the disease is an autoimmune disease. 
     
     
         3 . The method of  claim 1 , wherein the T-cell mediated disease is multiple sclerosis. 
     
     
         4 . The method of  claim 1 , wherein the antibody is a monoclonal antibody. 
     
     
         5 . The method of  claim 1 , wherein the subject is human. 
     
     
         6 . The method of  claim 5 , wherein the antibody is a humanized antibody. 
     
     
         7 . The method of  claim 6 , wherein the humanized antibody is selected from the group of antibodies consisting of Fab2, Fab4, and Fab6, or variants thereof including only conservative sequence modifications. 
     
     
         8 . The method of  claim 6 , wherein the humanized antibody comprises a heavy chain comprising SEQ ID NO: 1, a light chain comprising SEQ ID NO: 2, or variants thereof including only conservative sequence modifications. 
     
     
         9 . The method of  claim 6 , wherein the humanized antibody comprises a heavy chain comprising SEQ ID NO: 3, a light chain comprising SEQ ID NO: 4, or variants thereof including only conservative sequence modifications. 
     
     
         10 . The method of  claim 6 , wherein the humanized antibody comprises a heavy chain comprising SEQ ID NO: 5, a light chain comprising SEQ ID NO: 6, or variants thereof including only conservative sequence modifications.